Cargando…

Steroid conversion with CYP106A2 – production of pharmaceutically interesting DHEA metabolites

BACKGROUND: Steroids are lipophilic compounds with a gonane skeleton and play an important role in higher organisms. Due to different functionalizations - mainly hydroxylations - at the steroid molecule, they vary highly in their mode of action. The pharmaceutical industry is, therefore, interested...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmitz, Daniela, Zapp, Josef, Bernhardt, Rita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4080778/
https://www.ncbi.nlm.nih.gov/pubmed/24903845
http://dx.doi.org/10.1186/1475-2859-13-81
_version_ 1782324038775865344
author Schmitz, Daniela
Zapp, Josef
Bernhardt, Rita
author_facet Schmitz, Daniela
Zapp, Josef
Bernhardt, Rita
author_sort Schmitz, Daniela
collection PubMed
description BACKGROUND: Steroids are lipophilic compounds with a gonane skeleton and play an important role in higher organisms. Due to different functionalizations - mainly hydroxylations - at the steroid molecule, they vary highly in their mode of action. The pharmaceutical industry is, therefore, interested in hydroxysteroids as therapeutic agents. The insertion of hydroxyl groups into a steroid core, however, is hardly accomplishable by classical chemical means; that is because microbial steroid hydroxylations are investigated and applied since decades. CYP106A2 is a cytochrome P450 monooxygenase from Bacillus megaterium ATCC 13368, which was first described in the late 1970s and which is capable to hydroxylate a variety of 3-oxo-delta4 steroids at position 15beta. CYP106A2 is a soluble protein, easy to express and to purify in high amounts, which makes this enzyme an interesting target for biotechnological purposes. RESULTS: In this work a focused steroid library was screened in vitro for new CYP106A2 substrates using a reconstituted enzyme assay. Five new substrates were identified, including dehydroepiandrosterone and pregnenolone. NMR-spectroscopy revealed that both steroids are mainly hydroxylated at position 7beta. In order to establish a biotechnological system for the preparative scale production of 7beta-hydroxylated dehydroepiandrosterone, whole-cell conversions with growing and resting cells of B. megaterium ATCC1336 the native host of CYP1062 and also with resting cells of a recombinant B. megaterium MS941 strain overexpressing CYP106A2 have been conducted and conversion rates of 400 muM/h (115 mg/l/h) were obtained. Using the B. megaterium MS941 overexpression strain, the selectivity of the reaction was improved from 0.7 to 0.9 for 7beta-OH-DHEA. CONCLUSIONS: In this work we describe CYP106A2 for the first time as a regio-selective hydroxylase for 3-hydroxy-delta5 steroids. DHEA was shown to be converted to 7beta-OH-DHEA which is a highly interesting human metabolite, supposed to act as neuroprotective, anti-inflammatory and immune-modulatory agent. Optimization of the whole-cell system using different B. megaterium strains lead to a conversion of DHEA with B. megaterium showing high selectivity and conversion rates and displaying a volumetric yield of 103 mg/l/h 7beta-OH-DHEA.
format Online
Article
Text
id pubmed-4080778
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40807782014-07-03 Steroid conversion with CYP106A2 – production of pharmaceutically interesting DHEA metabolites Schmitz, Daniela Zapp, Josef Bernhardt, Rita Microb Cell Fact Research BACKGROUND: Steroids are lipophilic compounds with a gonane skeleton and play an important role in higher organisms. Due to different functionalizations - mainly hydroxylations - at the steroid molecule, they vary highly in their mode of action. The pharmaceutical industry is, therefore, interested in hydroxysteroids as therapeutic agents. The insertion of hydroxyl groups into a steroid core, however, is hardly accomplishable by classical chemical means; that is because microbial steroid hydroxylations are investigated and applied since decades. CYP106A2 is a cytochrome P450 monooxygenase from Bacillus megaterium ATCC 13368, which was first described in the late 1970s and which is capable to hydroxylate a variety of 3-oxo-delta4 steroids at position 15beta. CYP106A2 is a soluble protein, easy to express and to purify in high amounts, which makes this enzyme an interesting target for biotechnological purposes. RESULTS: In this work a focused steroid library was screened in vitro for new CYP106A2 substrates using a reconstituted enzyme assay. Five new substrates were identified, including dehydroepiandrosterone and pregnenolone. NMR-spectroscopy revealed that both steroids are mainly hydroxylated at position 7beta. In order to establish a biotechnological system for the preparative scale production of 7beta-hydroxylated dehydroepiandrosterone, whole-cell conversions with growing and resting cells of B. megaterium ATCC1336 the native host of CYP1062 and also with resting cells of a recombinant B. megaterium MS941 strain overexpressing CYP106A2 have been conducted and conversion rates of 400 muM/h (115 mg/l/h) were obtained. Using the B. megaterium MS941 overexpression strain, the selectivity of the reaction was improved from 0.7 to 0.9 for 7beta-OH-DHEA. CONCLUSIONS: In this work we describe CYP106A2 for the first time as a regio-selective hydroxylase for 3-hydroxy-delta5 steroids. DHEA was shown to be converted to 7beta-OH-DHEA which is a highly interesting human metabolite, supposed to act as neuroprotective, anti-inflammatory and immune-modulatory agent. Optimization of the whole-cell system using different B. megaterium strains lead to a conversion of DHEA with B. megaterium showing high selectivity and conversion rates and displaying a volumetric yield of 103 mg/l/h 7beta-OH-DHEA. BioMed Central 2014-06-05 /pmc/articles/PMC4080778/ /pubmed/24903845 http://dx.doi.org/10.1186/1475-2859-13-81 Text en Copyright © 2014 Schmitz et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Schmitz, Daniela
Zapp, Josef
Bernhardt, Rita
Steroid conversion with CYP106A2 – production of pharmaceutically interesting DHEA metabolites
title Steroid conversion with CYP106A2 – production of pharmaceutically interesting DHEA metabolites
title_full Steroid conversion with CYP106A2 – production of pharmaceutically interesting DHEA metabolites
title_fullStr Steroid conversion with CYP106A2 – production of pharmaceutically interesting DHEA metabolites
title_full_unstemmed Steroid conversion with CYP106A2 – production of pharmaceutically interesting DHEA metabolites
title_short Steroid conversion with CYP106A2 – production of pharmaceutically interesting DHEA metabolites
title_sort steroid conversion with cyp106a2 – production of pharmaceutically interesting dhea metabolites
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4080778/
https://www.ncbi.nlm.nih.gov/pubmed/24903845
http://dx.doi.org/10.1186/1475-2859-13-81
work_keys_str_mv AT schmitzdaniela steroidconversionwithcyp106a2productionofpharmaceuticallyinterestingdheametabolites
AT zappjosef steroidconversionwithcyp106a2productionofpharmaceuticallyinterestingdheametabolites
AT bernhardtrita steroidconversionwithcyp106a2productionofpharmaceuticallyinterestingdheametabolites